- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
- Interventions
- PLX3397, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 1,852
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, PD-L1 Gene Mutation, Advanced Treatment-Naïve PD-L1, Sitravatinib, Pembrolizumab
- Interventions
- Sitravatinib, Pembrolizumab
- Drug
- Lead sponsor
- Sarah Goldberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
- Interventions
- Pembrolizumab, Radiation therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Loren Mell, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • La Jolla, California • Tampa, Florida + 3 more
- Conditions
- Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory ALK Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Gray Zone Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Ontorpacept, Pembrolizumab, Positron Emission Tomography, Maplirpacept, Biopsy
- Procedure · Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Rochester, Minnesota
- Conditions
- Advanced Solid Tumor
- Interventions
- CLN-617, Pembrolizumab
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orlando, Florida • Chicago, Illinois + 2 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Lenvatinib, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 26
- States / cities
- Fresno, California • San Marcos, California • Aurora, Colorado + 22 more
- Conditions
- Recurrent Respiratory Papillomatosis
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Evanston, Illinois • Boston, Massachusetts
- Conditions
- Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- PANDA-VAC, Pembrolizumab
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Urothelial Carcinoma
- Interventions
- Zilovertamab vedotin, Pembrolizumab, MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 10
- States / cities
- Orange, California • San Francisco, California • Aurora, Colorado + 7 more
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
- Interventions
- XmAb®22841, Pembrolizumab (Keytruda®)
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
- Interventions
- CUE-101, Pembrolizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metastatic Lung Cancer, Stage IV Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Pembrolizumab
- Radiation · Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- isunakinra
- Drug
- Lead sponsor
- Buzzard Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Atlanta, Georgia
- Conditions
- Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
- Interventions
- Pembrolizumab, Trastuzumab, ado-trastuzumab emtansine, Cetuximab
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Endometrial Cancer, Urothelial Carcinoma (UC), Breast Cancer
- Interventions
- STRO-006, Pembrolizumab
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 3 more
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
- Interventions
- FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
- Conditions
- Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Sacituzumab Govitecan, Pembrolizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- Enfortumab Vedotin, Pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Stanford, California • Chicago, Illinois + 16 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Pegylated Recombinant Human Hyaluronidase PH20, Pembrolizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastric Cancer, Stomach Cancer, Esophageal Cancer
- Interventions
- Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 11
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
- Interventions
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Biological · Drug
- Lead sponsor
- Rapa Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Advanced Solid Tumor
- Interventions
- OMTX705, Pembrolizumab, Tislelizumab (BGB-A317)
- Drug
- Lead sponsor
- Oncomatryx Biopharma S.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts